



**Mike Recher**

**Kontakt**

Mike Recher

## Publikationen (10)

Burgener A, Dimeloe S, Lötscher J, Sauder U, Ebnöther M, Burger B, Heijnen I, Martínez-Cano S, Cantoni N, Brücker R, Kahlert C, Sancho D, Jones R, Navarini A, Recher M, Epple R, Grähler J, Müller-Durovic B, Bantug G, Meyer B, Higgins R, Ghosh A, Bignucolo O, Ma E, Loeliger J, Unterstab G, Geigges M, Steiner R, Enamorado M, Ivanek R, Hunziker D, Schmidt A, Hess C. SDHA gain-of-function engages inflammatory mitochondrial retrograde signaling via KEAP1-Nrf2. *Nat Immunol* 2019; 20:1311-1321.

Berner F, Hartmann F, Cheng H, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy A, Jochum W, Speiser D, Zippelius A, Läubli H, Bomze D, Diem S, Ali O, Fässler M, Ring S, Niederer R, Ackermann C, Baumgaertner P, Pikor N, Cruz C, van de Veen W, Akdis M, Nikolaev S, Flatz L. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. *JAMA Oncol* 2019; 5:1043-1047.

Diem S, Risch M, Recher M, Risch L, Dummer R, Levesque M, Mangana J, Hillmann D, Niederer R, Berner F, Ali O, Bomze D, Fässler M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. *J Immunother* 2019; 42:89-93.

Fässler M, Jörger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D, Ludewig B, Levesque M, Dummer R, Siano M, Krolík M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Pérez Shibayama C, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. *J Immunother Cancer* 2019; 7:50.

Quteineh L, Mohacsi P, Dufour J, Soccal P, Kutalik Z, Marques-Vidal P, Vollenweider P, Recher M, Hess C, Pascual M, Eap C, Steiger J, Van Delden C, Wójtowicz A, Bochud P, Crettol S, Vandenberghe F, Venetz J, Manuel O, Golshayan D, Lehmann R, Mueller N, Binet F, Swiss Transplant Cohort Study. Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients. *Am J Transplant* 2018; 19:238-246.

Navarini A, Bignucolo O, Meyer B, Meienberg F, Mehling M, Jeker L, Heijnen I, Daikeler T, Gebbers J, Grimbacher B, Sansom D, Jeker R, Hess C, Jauch A, Kistner A, Bigler M, Hruz P, Berger C, Hou T, Schwab C, Gabrysch A, Higgins R, Frede N, Padberg S, Kämpe O, Burgener A, Marquardsen F, Baldin F, Recher M. Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis. *J Allergy Clin Immunol* 2016; 139:1043-1046.e5.

Lang P, Zinkernagel R, Ohashi P, Häussinger D, Harris N, Hengartner H, Ludewig B, Kalinke U, Van Rooijen N, Cervantes-Barragan L, Kulawik A, Meryk A, Krings C, Gailus N, Borkens S, Scheu S, Honke N, Recher M, Lang K. Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon-I-dependent manner in mice. *Hepatology* 2010; 52:25-32.

Lang P, Ohashi P, Ludewig B, Honda K, Bergthaler A, Flatz L, Pellegrini M, Recher M, Navarini A, Verschoor A, Cervantes-Barragan L, Lang K. Hematopoietic cell-derived interferon controls viral replication and virus-induced disease. *Blood* 2009; 113:1045-52.

Lang P, Bader M, Graf R, Clavien P, Hegazy A, Löhning M, Harris N, Ohashi P, Hengartner H, Zinkernagel R, Odermatt B, Merkler D, Contaldo C, Georgiev P, El-Badry A, Recher M, Kurrer M, Cervantes-Barragan L, Ludewig B, Calzascia T, Bolinger B, Lang K. Aggravation of viral hepatitis by platelet-derived serotonin. *Nature medicine* 2008; 14:756-61.

Navarini A, Hengartner H, Odermatt B, Landmann R, Bille J, Flatz L, Bergthaler A, Meury S, Georgiev P, Lang K, Recher M, Zinkernagel R. Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responses. *Proc Natl Acad Sci USA* 2006; 103:15535-9.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)